Chemotherapy, AdjuvantAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyBreast NeoplasmsTreatment OutcomeNeoplasm StagingCyclophosphamideDisease-Free SurvivalAdjuvants, ImmunologicFluorouracilRadiotherapy, AdjuvantCisplatinPrognosisDoxorubicinSurvival AnalysisAntineoplastic AgentsNeoplasm Recurrence, LocalSurvival RateMethotrexateNeoadjuvant TherapyLymphatic MetastasisFollow-Up StudiesTegafurDrug Administration ScheduleEpirubicinAntimetabolites, AntineoplasticLung NeoplasmsAdjuvants, PharmaceuticFreund's AdjuvantLevamisoleRetrospective StudiesColonic NeoplasmsAdenocarcinomaAnthracyclinesMastectomyPaclitaxelTime FactorsProspective StudiesKaplan-Meier EstimateTaxoidsTamoxifenCarboplatinColorectal NeoplasmsRandomized Controlled Trials as TopicCarcinoma, Non-Small-Cell LungVinblastineStomach NeoplasmsClinical Trials as TopicGastrectomyTumor Markers, BiologicalPneumonectomyNeoplasm MetastasisOrganoplatinum CompoundsMultivariate AnalysisLeucovorinCystectomyAntineoplastic Agents, HormonalReceptors, EstrogenEtoposideProportional Hazards ModelsLomustineSarcomaRectal NeoplasmsDeoxycytidineUracilOsteosarcomaAntineoplastic Agents, AlkylatingPremenopauseReceptor, erbB-2Lymph Node ExcisionOxonic AcidRisk FactorsRecurrencePostoperative ComplicationsTesticular NeoplasmsRadiotherapyMitomycinLymph NodesOvarian NeoplasmsIfosfamideBone NeoplasmsPostoperative CareAntibiotics, AntineoplasticSemustineThiotepaCarcinomaMenopauseBleomycinAntineoplastic ProtocolsAge FactorsAmenorrheaPredictive Value of TestsClinical Trials, Phase III as TopicQuality of LifeReceptors, ProgesteroneSoft Tissue NeoplasmsDrug Resistance, NeoplasmMedical OncologyChemoradiotherapy, AdjuvantRadiotherapy Dosage